The TPU’s mission is to develop scientific and scalable commercial solutions that prevent obesity and its consequences for people at the greatest risk.
By combining Novo Nordisk’s scientific insights with clinical data as well as public health data and information, this unit aims to identify people at high risk for developing obesity and deliver targeted interventions that can stop them from developing the disease in the first place. An important principle of the TPU’s work is to build novel, multi-sector partnerships that combine the required scientific, technological and implementation expertise to deliver impactful prevention solutions.
Preventing, detecting and managing obesity could be seen as the single most important way to reduce premature deaths due to cancer, cardiovascular diseases and diabetes, which are the main causes of death worldwide (Source: World Obesity Atlas 2024).
Nadeem Sarwar, Corporate Vice President, is the TPU Head and Co-Founder with a background in scientific and business models encompassing genomics, data sciences and digital technologies for therapeutic and health innovation.
Scott Small is the Senior Director in the TPU Product Innovation Lab. His career so far includes 15 years in laboratory, clinical trial, population health and wearable tech research at the intersection of academia, healthcare, and the medical device industry.
